Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies-Reference-Cited by-同舟云学术

Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies

Published:2024-08-15 Issue: Volume: Page:1-13
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Lou Yidan¹²^ORCID,Chen Yijing¹²,Guo Kaibo²³,Li Binbin²⁴,Zheng Song¹²³⁴

Affiliation:

1. Zhejiang University School of Medicine, Hangzhou, 310006, China

2. Department of Oncology, Hangzhou First People's Hospital, Hangzhou, 310006, China

3. Key Laboratory of Clinical Cancer Pharmacology & Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Westlake University, Hangzhou, 310006, China

4. Department of Oncology, The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310006, China

Funder

Hangzhou Biomedical and Health Industry Development Support Science and Technology Special Fund

Major Projects of Hangzhou Health Science and Technology Plan

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17520363.2024.2385297

Reference115 articles.

1. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care

2. Incidence and Overall Survival of Biliary Tract Cancers in South Korea from 2006 to 2015: Using the National Health Information Database

3. Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

4. Cholangiocarcinoma — evolving concepts and therapeutic strategies

5. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer